Stocks to Watch for March 15th: ATAI - CCO - CGIX - JOEZ - ZQK - ATV - BWEN - CNAM - CYTX - WILC:

Stocks to Watch on Monday March 15th, 2010:

LONG:

ATAI:



CCO:



CIGX:



JOEZ:



ZQK:



SHORT:

ATV:



BWEN:



CNAM:



CYTX:



WILC:

ADVENTRX Receives Brand Name Acceptance for ANX-530:

ADVENTRX Receives Brand Name Acceptance for ANX-530:

SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the U.S. Food and Drug Administration (FDA) has accepted the proposed proprietary name "Exelbine™" for the Company's product candidate ANX-530 (vinorelbine injectable emulsion).

"We are pleased with the FDA's response to our proprietary name request and look forward to continued regulatory progress on ANX-530," said Brian M. Culley, Chief Executive Officer of ADVENTRX.

Following completion of its review process, the FDA concluded that "Exelbine" is acceptable provided the information presented by ADVENTRX regarding the safety of interchanging ANX-530 with other vinorelbine injectable products is confirmed during review of an ANX-530 New Drug Application (NDA).

As previously announced, the Company submitted an NDA for ANX-530 to the FDA in December 2009. In March 2010, the Company announced that it had received a refusal-to-file letter from the FDA regarding its ANX-530 NDA submission. In the letter, the FDA indicated that the data included in the December 2009 NDA submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. The FDA identified only this one chemistry, manufacturing and controls (CMC) reason for the refusal to file. ADVENTRX has requested a face-to-face meeting with the FDA to understand its requirements and define the path to a successful filing of an ANX-530 NDA at the earliest possible time.

About ADVENTRX Pharmaceuticals:

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com.

http://www.prnewswire.com/news-releases/adventrx-receives-brand-name-acceptance-for-anx-530-87453562.html

ANX closed at $0.21 yesterday, and hit $0.29 in the pre-market session this morning:

Analyst's Upgrade And Raise Price Targets For ITMN - InterMune Inc.

Thomas Weisel Partners More Than Double InterMune (ITMN) Price Target To $55

http://www.benzinga.com/analyst-ratings/analyst-color/166370/thomas-weisel-partners-more-than-doubles-intermune-itmn-price-t

Wells Fargo Upgrades InterMune (ITMN) to Outperform:

http://www.streetinsider.com/Upgrades/Wells+Fargo+Upgrades+InterMune+(ITMN)+to+Outperform/5424826.html

Top 10 Analyst Upgrades and Downgrades (ADI, NLY, BIDU, CVX, ESLR, ITMN, JCG, LMT, SONC, VALE)

Posted: March 10, 2010 at 8:22 am

These are this Wednesday’s top 10 analyst upgrades, downgrades, and initiations seen from Wall Street morning research calls:

Analog Devices Inc. (NYSE: ADI) Raised to Outperform at Bernstein.
Annaly Capital Management (NYSE: NLY) Cut To Neutral at JPMorgan.
Baidu, Inc. (NASDAQ: BIDU) Reiterated Buy but Target raised to $630 from $550 at Citigroup.
Chevron Corp. (NYSE: CVX) Cut to Neutral at BofA/Merrlill Lynch.
Evergreen Solar (NASDAQ: ESLR) Started as Hold at Wunderlich.
InterMune Inc. (NASDAQ: ITMN) Raised to Buy at ThinkEquity; Raised to Outperform at Wells Fargo.
J. Crew Group, Inc. (NYSE: JCG) Cut to Hold at Citigroup.
Lockheed Martin (NYSE: LMT) Raised to Neutral at Macquarie.
Sonic Corp. (NASDAQ: SONC) Raised to Buy at KeyBanc.
Vale SA (NYSE: VALE) Cut to Neutral at UBS.

http://247wallst.com/2010/03/10/top-10-analyst-upgrades-and-downgrades-adi-nly-bidu-cvx-eslr-itmn-jcg-lmt-sonc-vale/

Happy Trading,
zigzagman

ITMN - FDA Panel Favors Approval For Intermune Inc. Drug:

FDA panel favors approval for InterMune drug:

By: The Associated Press | 09 Mar 2010 | 04:47 PM ET

WASHINGTON - Federal health advisers on Tuesday voted in favor of an experimental drug from InterMune Inc., despite mixed evidence of whether it provides significant benefits for patients with a rare lung disease.

The Food and Drug Administration's panel of lung experts voted 9-3 to recommend approval of the company's drug pirfenidone. That recommendation followed a narrower 7-5 vote that the drug provides a "clinically meaningful benefit" for patients with idiopathic pulmonary fibrosis, an often fatal lung disease for which there are no approved drugs.

The FDA is not required to follow the group's advice, though it often does. The agency is scheduled to make its final decision by May 4.

Ultimately, the lack of options for patients with idiopathic pulmonary fibrosis, or IPF, appeared to sway a majority of panelists in the drug's favor.

"IPF is a fatal disease and you have to offer your patients hope," said Karen Gottesman, the panel's patient representative. "If this drug can offer your patients even a smidgen of hope, it's worth approving."

Intermune submitted two studies for its drug to FDA, measuring ability to improve lung function in patients. While one study showed a statistically significant 4.4 percent increase in lung strength, another failed to achieve significance compared with placebo.

The FDA usually requires two placebo-controlled trials showing meaningful results to grant approval, a fact cited by several panelists who voted against the drug's benefits.

"We have two competing studies here," said Dr. Peter Terry, of Johns Hopkins University Medical Institutions. "Based on the agency's requirement for substantial evidence I don't think this meets the criteria for clinically meaningful benefit."

Most panelists agreed the drug's effect was modest and that long-term follow-up would be needed to determine whether it can extend patient survival. While slightly more patients taking pirfenidone survived compared with patients taking placebo, there wasn't an overall survival benefit in the company's studies, according to the FDA.

"Some people were expecting a cure, this is not a cure," said Dr. Richard Honsinger, of Los Alamos Medical Center. "This drug just slows the decline caused by the disease."

In a separate vote, panelists ruled 9-3 that pirfenidone was safe for patients. Most panelists said side effects such as nausea, rash and fatigue were tolerable, considering the fatal nature of the disease.

While some pirfenidone patients experienced abnormalities in liver function, those issues mostly resolved after patients discontinued the drug.

About 200,000 people in the U.S. and Europe have idiopathic pulmonary fibrosis. The disease causes scarring and stiffening of the lungs, which makes it increasingly difficult to breathe over time. The cause of the disease is unknown.

Intermune Chief Medical Officer, Dr. Steven Porter said he was "very excited," by the meeting's outcome.

"I think it was a very productive discussion and the data spoke for itself," said Porter.

If approved, InterMune plans to market the drug in the U.S. under the name Esbriet. The drug was approved in Japan in October 2008, where it is sold under the name Pirespa by Shionogi and Co.

Shares of the Brisbane, Calif.-based company were halted in trading Tuesday ahead of the FDA's meeting. The stock closed at $23.30 Monday.

Last week shares jumped to their highest point since 2007 after the FDA posted its review of pirfenidone.

http://www.cnbc.com/id/35783566/site/14081545/for/cnbc/

Here is one of the first PR's I saw after the FDA Advisory Panel gave it's decision:

U.S. FDA Panel Backs InterMune Lung Drug:

Tue Mar 9, 2010 3:39pm EST

Final agency decision expected by May 4.

SILVER SPRING, Md., March 9 (Reuters) - U.S. medical advisers backed InterMune Inc's (ITMN.O) experimental drug to treat lung scarring on Tuesday, saying it should be approved for patients with the rare fatal condition.

In a 9-3 vote, the Food and Drug Administration's outside experts said the company's data were strong enough to support use of the drug, pirfenidone, for patients with idiopathic pulmonary fibrosis (IPF).

InterMune is seeking FDA approval of pirfenidone to help mitigate worsening lung function in patients with IPF, a fatal condition in which the lungs scar for no apparent cause.

Trading in shares of InterMune was halted ahead of the panel's vote.

http://www.reuters.com/article/idUSN0924859020100309

Here are two charts showing ITMN's big move up as soon as the trading halt was lifted at 4:30pm ET...It immediately shot up to the $38.00 range, and it's After-Hours high was $38.62

ITMN closed yesterday at $23.30 and the closing price on March 4th was $14.31

CONGRATULATIONS! to ITMN, and it's shareholders.

This is great news for the people who need this drug, since there is currently no approved drug for their condition.

Happy Trading,
zigzagman





ITMN closed yesterday at $23.30 and the closing price on March 4th was $14.31 !!!...

InterMune Inc. - ITMN Shares Hang on FDA Playing the “make or break” event with options:

InterMune (ITMN) Shares Hang on FDA Playing the “make or break” event with options:

by Kevin Cook March 8, 2010 4:06 EST

Kevin Cook is an options instructor for the Options News Network. He was an institutional foreign exchange market maker and arbitrageur for nine years, where he worked with futures.

http://www.onn.tv/buy-and-trade/intermune-itmn-shares-hang-on-fda/

We know that the stocks of young biotech companies with experimental drugs in the works trade “make or break” around FDA approval events. Friday’s action in InterMune (NASDAQ: ITMN), which sent the shares up over 60%, was another classic example and something we had been anticipating since January 4th when the FDA granted “Priority Review” status to ITMN’s idiopathic pulmonary fibrosis drug, pirfenidone.

Last week, I decided to write—for the next 20 weeks—about all 20 stocks in my favorite biotech ETF, the FBT. This week was made for ITMN, one of the top-ten holdings, with its scheduled FDA review date of March 9th and stock-moving news posted Friday in briefing documents on the FDA website. The optimism expressed in ITMN’s rally is built around speculation that the FDA analysis of pirfenidone’s Phase 3 clinical trials may be more favorable than previously expected.

The final word of approval from the FDA for pirfenidone is not due until May 4th, but the company and investors may be hanging their fortunes on the fact that the findings of Advisory Committee meetings, like tomorrow’s, are often the direction the agency is headed. In other words, while the FDA is not held to judgments by its advisory panels, it usually follows them. Before we look at how options traders might be playing the event, let’s review some of the key facts about InterMune and pirfenidone.

Key Facts on ITMN:

InterMune, Inc. is a biotechnology company focused on developing and commercializing innovative therapies in pulmonology and hepatology. Their only drug approved in the U.S. currently is Actimmune, which treats both CGD and severe, malignant osteopetrosis, two rare congenital disorders.

Pirfenidone is the only drug designed to treat idiopathic pulmonary fibrosis (IPF), an unexplained inflammation and scarring of the lungs, which hinders the ability to process oxygen and causes shortness of breath. A progressive disease, symptoms increase in severity and usually result in death within two to five years of diagnosis.

200,000 people are affected by IPF in US and Europe; there are an estimated 30,000 new cases each year.

Pirfenidone is approved and marketed in Japan as Pirespa
FDA granted Fast Track/Priority Review status for the US New Drug Application (NDA) on January 4, 2010.

On Friday March 5, FDA posted a March 9 Review briefings document, signaling that prior criticisms of ITMN research may be alleviating.

Proposed U.S. name for pirfenidone is Esbriet.

Neutral and Bearish Strategies:

For investors and traders who believe that we won’t know enough after tomorrow to take ITMN’s stock above $30 or below $15, this short iron condor offers significantly high implied volatility to temper the risk. We recommended this play in our Trading Ideas section on Friday when it was garnering only $2.50 in total premium. With implied volatility climbing yet again today to over 300%, this iron condor could now collect more than $3.00.



And for those who think that a severe disappointment and pullback is likely after tomorrow, in our OTA Portfolio we looked at a bear ratio put strategy where you could buy a March 17.5 put and sell two 12.5 puts for nearly even money. With essentially zero cash outlay, and a max profit potential of $5.00, this play doesn’t begin to lose money unless the stock falls below $7.50. (The chart below was created with a virtual trading account, something I recommend especially for anyone who wants to experiment with new option strategies).



All of these March strikes have seen significant trading today with the March 30/35 call spread trading over 10,000 by noon and now edging closer to 20,000 contracts each as the day winds down. On the put side, the March 12.5 and 15 puts have seen more than 12,000 contracts trade in each, while the 17.50, 10, and 7.50 strikes all have close to 5,000 contracts. All of these volumes are well above normal and indicate many players positioning for any possible news tomorrow.

Short Interest and Insider Buying:

Also worth noting about ITMN shares is that since the early January announcement about FDA’s track for approval of pirfenidone, short interest in the stock climbed significantly from around 11% of float to near 16%. This may explain much of the move we saw Friday that vaulted the shares from below $15 to above $25 at one point.

And late January saw significant buying by insiders, with Director Jonathan Leff buying 2.1 million shares at $14.10 and Director James Healy exercising 5,000 options at $4.50 per share.

ITMN - InterMune Inc. - A Stock To Watch Next Week - March 8th-12th, 2010:

ITMN - InterMune Inc. - Healthcare - Biotechnology

Website: http://www.intermune.com/wt/home

Friday's news release from the company website that caused the huge gap up at the opening bell:

http://phx.corporate-ir.net/phoenix.zhtml?c=100067&p=irol-newsArticle&ID=1399323&highlight=

Another news release released on Friday:

InterMune Stock Gets Boost as FDA Staff Questions Lung Drug:

http://blogs.wsj.com/health/2010/03/05/intermune-stock-gets-boost-as-fda-staff-questions-lung-drug/?mod=yahoo_hs

By James A. White

The FDA staff said it has a bunch of questions about InterMune’s new drug to slow deteriorating lung functioning. But investors figure the concerns weren’t as bad as they could have been, sending the biotech’s shares soaring.

The stock jumped as much as 74% after FDA reviewers said only one of InterMune’s two late-stage trails for the experimental drug pirfenidone had met its main goal and added that “the clinical significance of the treatment effect size is uncertain.”

The FDA documents, which were released ahead of an advisory panel meeting to discuss the drug Tuesday March 9th, also had a mix of other things to say.

All things considered, an Oppenheimer analyst noted the “tone was less negative than expected,” all things considered and there was room for the drug to still get FDA approval. The shares settled down in later trading, but still finished up nearly 60% for the day.

InterMune often appears on lists of likely biotech takeover candidates. FDA approval of pirfenidone would give it two drugs on the U.S. market.

The new drug would treat idiopathic pulmonary fibrosis, which affects about 200,000 Americans, the majority of whom eventually die of respiratory failure. The FDA noted that there aren’t any approved drugs to treat IPF, although drugs like corticosteroids and drugs that suppress the immune system are used, according to Dow Jones Newswires.

The company also put out material noting that “the slowing of progression in loss of lung volume constitutes a clear benefit to patients,” Reuters said.

Here’s more news that came out on Friday about ITMN:

http://www.prnewswire.com/news-releases/intermune-announces-posting-of-briefing-documents-for-fda-advisory-committee-meeting-on-pirfenidone-86546937.html

http://www.forbes.com/2010/03/05/intermune-fda-drug-markets-equities-pharma-update.html?partner=yahootix

http://finance.yahoo.com/news/InterMune-Shoots-Higher-On-ibd-3578098094.html?x=0&.v=1

http://www.foxbusiness.com/story/markets/industries/health-care/fda-posts-documents-briefing-new-drug/

The last paragraph of this article mentions ITMN may be a buyout target by a big pharma company:

http://blogs.wsj.com/health/2009/08/21/is-1-billion-is-the-right-price-for-pharma-ma/

Here is some Fundamental Analysis information:

Look at the difference in the numbers shown by the Yahoo Finance and the Finviz.com sites. Notice the differences between the Float numbers, the percentage of shares owned by Institutions, and the percentage of shares owned by Insiders. There is also a large difference in the number and the percentage of shares that are Short.

That's probably due to when each site updates their data. I usually prefer to get my information from Yahoo Finance, because they usually update their data faster than Finviz.com does.

I read on the IHUB message board that Insiders recently purchased 30 million shares, but I haven't been able to verify that yet. That may account for the differences between the Yahoo Finance and the Finviz.com information.

The Yahoo Finance numbers:



The Finviz.com numbers:





Look at all of the Insider Transactions for January 26th, 2010. Insiders started buying again on that date, which is a vote of confidence from the people that run this company:



But here, Yahoo Finance missed Oppenheimer's reiteration of an Outperform rating on January 25th, 2010.

Yahoo Finance:



Finviz.com:



Here is an hourly, daily, and a weekly chart of ITMN. There is a short YouTube video below these chartrs that shows Technical Analysis of these charts.







Here is the Option Chain for ITMN as of the close on Friday March 5th, 2010. These Options expire on the third Friday in March, which is March 19th, 2010:



Here's a nine minute YouTube video that analyzes ITMN's charts:



Happy Trading,
zigzagman

ZANE - Zanett Inc. Releases A Press Release Today And Was UP 582%!...

About Zanett, Inc.

Zanett is a leading business process outsourcing (BPO), IT enabled services (ITES), and information technology (IT) consulting firm serving Fortune 500 corporations and mid-market organizations in Healthcare, Life Sciences, Manufacturing & Distribution, Retail, Gaming & Hospitality, and State & Local Government.

Zanett helps organizations align business objectives with outsourced technology-enabled services to create Real Enterprise Value. We serve the Fortune 500 and mid-market organizations in Health care, Life Sciences, Manufacturing & Distribution, Retail, Gaming & Hospitality, and State & Local Government with solutions ranging from business consulting as well as custom business solutions that integrate and implement Oracle's full suite of product offerings Oracle, JD Edwards, PeopleSoft, Seibel, including infrastructure technology and managed services together with associated Oracle Fusion technologies. Zanett employs over 225 professionals in North America and Asia with offices in Atlanta, Boston, Cincinnati, Indianapolis, Jacksonville, New York City, North Palm Beach, and Manila. For more information please visit http://www.zanett.com/ or http://healthcare.zanett.com.

Here is the Press Release they put out today, and was the reason for the massive move up of the share price of their stock:

http://zanett.investorroom.com/index.php?s=43&item=74

Record Contracts Signed in Jan + Feb for Zanett:

Over $12 million Among 42 Customers - Healthcare Focus on Target:

NEW YORK, March 4 /PRNewswire/ -- Zanett, Inc. today announced that it has set an in-house corporate record for contracts closed in the months of January and February 2010. Between the two months, over $12 million dollars in new business has been closed. This amount of revenue is comprised of 42 different customers, with the largest customer being responsible for a $4 million mandate.

HEALTHCARE FOCUS – SOFTWARE PACKAGE

Healthcare was by far the biggest segment of contracts signed for the past 2 months. Zanett recently announced that is has jointly developed a CODS software package (Clinical Online Delivery System) to support standardized, evidence-based order sets at the point of care, arming doctors and clinicians with critical information to improve medication safety and patient care. With this solution, physicians and nurses will be able to spend more time with patients and less time on the charting required of them in creating paper records.

BUSINESS IS BOOMING – U.S. CAPITAL SPENDING UP

Dennis Harkins, President of Zanett, said, "All I can say is... Business is booming...! Throughout the US, corporations are currently hesitant about hiring individuals, due to unknown and unfunded mandates from Washington DC, so they are spending their money on increased capital expenditures. For any corporation out there, Oracle ERP and other IT spending are a natural beneficiary of a reduction in labor force. Here at Zanett, we have 21 great people in our national salesforce, and we are currently accelerating full speed ahead, firing on all 12 cylinders."

IN-HOUSE RECORD CLOSINGS – OLD RECORD TO BE BEAT

Last quarter (Q4 2009) was a record quarter at Zanett as far as contracts closed, with over $13.7 million signed. Zanett management believes that, at this rate, this quarter (Q1 2010) will easily overtake last quarter and be a new in-house quarterly record.

One reason it moved up so much today is the fact that it's O/S (Outstanding Shares) and it's Float are very small. It's O/S is only 8.74 million shares, and it's Float is an amazingly low 3.67 million shares. Today, it traded more than twice it's Float! And it's average daily volume is only 16.2 thousand. Today it traded 8.1 million shares! That's a huge difference between 16.7 thousand, and 8.1 million shares traded per day.



Here is a screen shot of the fifteen-minute chart of ZANE for today, that shows it was running with huge volume behind it.



And here is a six month-daily chart that shows it ran flat the entire period until today's news sent it into orbit. If you expand this chart out to a one year period, it looks very much the same. It ran totally flat for over a year until today:



If we zoom in to a one month-daily chart, you'll see the huge volume spike from today, and all of the technical indicators are shooting straight up:



Congratulations! to all of the shareholders of this company. I've never heard of ZANE before today, but it is most certainly on my radar now!

The BIG Question now is: What will it do next? While it was a wonderful day for shareholders of this company that owned this stock, entering at this time can be a tricky proposition IMO.

Will it keep running? Will it pull back and give up half, three quarters, or almost all of today's gains? I'm sure we'll find that out tomorrow and next week.

This stock is traded on the Nasdaq exchange, but since it's under five dollars per share, it can't be Shorted using most U.S. online brokers. And to be honest, Shorting this stock doesn't seem like it would be a very good idea after the great news it put out today, and the stellar rise in the stock's share price.

If it breaks above today's intraday high of $2.50 tomorrow or early next week on high volume, this one may still have a very good chance of going higher. If the body of tomorrow's daily candlestick closes more than halfway down of the body of today's candlestick, that is usually considered to be Bearish.

When a stock runs flat with hardly any volume for over a year and then something happens like we saw today's PR and huge volume spike, that is usually a very Bullish occurrence. It makes a lot of traders and institutions sit up and take notice.

The next few trading sessions should be very interesting, and I will be keeping a very close eye on this company from now on.

Here are some of the other news articles from other stock market news sites that are talking about Zanett's impressive move up today:

The Strange Case Of Zanett Inc.

http://blogs.barrons.com/techtraderdaily/2010/03/04/the-strange-case-of-zanett-inc/?mod=yahoobarrons

Zanett Volume Spikes on Contract Bookings

http://www.thestreet.com/_yahoo/story/10695831/1/zanett-volume-spikes-on-contract-bookings.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA

Record Contracts Signed in Jan + Feb for Zanett; Over $12 million Among 42 Customers; Healthcare Focus on Target

http://finance.yahoo.com/news/Record-Contracts-Signed-in-prnews-1972871742.html?x=0&.v=1

I'm sure there will be a lot more chatter about this company tonight. I just added a Google Alert for this stock, and I will add any more news about this as I see it.

But one thing to think about is this news release put out yesterday, that states ZANE is about to receive a de-listing notice from the Nasdaq exchange for not meeting it's minimum share price of one dollar per share for more than 30 days.

http://finance.yahoo.com/news/Zanett-Inc-Expects-to-Receive-prnews-3282971503.html?x=0&.v=1

BACKGROUND INFORMATION

On September 17, 2009, Zanett, Inc. (the "Company") received a letter from Nasdaq notifying it that the bid price per share for the Company's common stock has closed below the $1.00 minimum bid price requirement for 30 consecutive trading days and that, as a result, the Company no longer meets minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2). No breach of any other listing requirement was listed in the letter.

Pursuant to Listing Rule 5810(c)(3)(A), the Company had 180 calendar days, or until March 15, 2010, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's common stock must close above $1.00 for a minimum of ten consecutive trading days. However, Nasdaq may, in its discretion, require the Company to maintain a minimum closing bid price of $1.00 per share for a period in excess of ten consecutive trading days (but generally no longer than 20 consecutive business days) before determining that the Company has demonstrated an ability to maintain long-term compliance with the rule.

Whatever happened today to make the share price rise above the one dollar minimum worked, but now they have to keep it there for thirty days to avoid de-listing from the Nasdaq exchange. This is so interesting in light of this last news release, I feel that more investigation seems appropriate.

Happy Trading,
zigzagman

JASO - Fundamental & Technical Analysis of JA Solar Holdings Co. Inc.

Someone requested that I do an analysis of the stock JASO.

This short ten minute video shows how I do Fundamental Analysis and Technical Analysis of the daily and weekly charts of JA Solar Holdings, which is a company based in Shanghai China and trades in the U.S. on the Nasdaq exchange under the ticker symbol JASO.

About JA Solar Holdings:

JA Solar Holdings Co. Ltd. through its subsidiaries, engages in the design, manufacture, and marketing of high-performance solar cells. It offers monocrystalline and multicrystalline solar cells. The company sells its products to solar module manufacturers who assemble and integrate solar cells into modules and systems that convert sunlight into electricity for power generation. JA Solar Holdings Co., Ltd. has operations in the People’s Republic of China, Spain, and rest of the world. The company was founded in 2005 and is based in Shanghai, the People’s Republic of China.

Disclaimer: I am not a licensed broker, and everything I say in this video is for educational purposes only. In no way am I making a recommendation to Buy, Hold, or Sell this stock.

ANX - ADVENTRX Pharmaceuticals Receives Refusal to File Letter from FDA on ANX-530 New Drug Application:

ADVENTRX Receives Refuse to File Letter from FDA on ANX-530 New Drug Application:

http://finance.yahoo.com/news/ADVENTRX-Receives-Refuse-to-prnews-815147953.html?x=0&.v=1

Press Release Source: ADVENTRX Pharmaceuticals, Inc.
On Monday March 1, 2010, 1:00 am

SAN DIEGO, March 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it received a refuse to file letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ANX-530 (vinorelbine injectable emulsion). In the letter, the FDA indicated that the data included in the initial submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. FDA identified only the one chemistry, manufacturing and controls (CMC) reason for the refusal to file. ADVENTRX plans to meet with the FDA as soon as possible to discuss its response.

To support a commercially-viable expiration dating period, the stability data provided in the ANX-530 NDA met ICH filing requirements for a new drug. Site-specific stability data from lots manufactured at the intended commercial manufacturing site also were submitted in the NDA.

"We believed, following discussions with the FDA at a pre-NDA meeting, the stability data package included in our initial submission supported both NDA acceptance and appropriate expiration dating. However, we now expect FDA will require additional site-specific stability data to accept our application. Although we plan to discuss the particular filing requirements with the reviewing chemists, site-specific stability studies are already ongoing and our recent financings provide us the capital to continue this work and, we expect, resubmit the application," said Brian M. Culley, Chief Executive Officer at ADVENTRX.

"We will work closely with the Agency to understand its new requirements and define the path to a successful resubmission at the earliest possible time," Mr. Culley continued.

ADVENTRX submitted the NDA for ANX-530 on December 30, 2009. Based on current regulations, once an NDA is submitted to the FDA, FDA has 60 days to preliminarily review the NDA submission and assess whether the NDA is sufficiently complete to permit a substantive review. If it determines that the NDA is not sufficiently complete, the FDA issues a refuse to file letter to the applicant. ADVENTRX plans to request a meeting with the FDA as soon as possible to discuss its comments on the NDA submission and to reach an understanding on what would be required for the ANX-530 NDA to be accepted for review.

Conference Call and Webcast

ADVENTRX will hold a conference call on Monday, March 1, 2010 beginning at 9:00 a.m. Eastern time to review the developments discussed in this news release. Individuals interested in listening to the conference call may do so by dialing (866) 305-6438 for domestic callers, or (706) 679-7161 for international callers, or from the webcast on the investor relations section of the Company's Web site at www.adventrx.com. A 48-hour telephone replay will be available approximately one hour after the conclusion of the call by dialing (800) 642-1687 for domestic callers, or (706) 645-9291 for international callers, and entering reservation code 60223016. The webcast will be available on the Company's Web site for 14 days following the completion of the call.

This news comes as a complete surprise. It looks like management really dropped the ball on this NDA application, and appears at this point to be totally incompetent. They had meetings with the FDA before submitting the NDA, and should have been aware of exactly what kind of information the FDA wanted them to submit for the application to get approval.

ANX - ADVENTRX Pharmaceuticals Is Expecting FDA News This Week:

ANX submitted a NDA (new drug application) to the FDA during the last week of December 2009, and the FDA has sixty days to give the company it's decision if it will accept the application or issue a RTF Letter (refusal to file letter). That means that the company most likely has already received the FDA's decision, and they have 72 hours after receiving the decision to issue a Press Release about the decision. There should be a PR about this released during the week of March 1st to March 5th 2010.

There has been a lot of talk this weekend if the FDA accepts the NDA for ANX-530 will it be eligible for either Fast Track or Priority Status, which would reduce the number of months until it's PDUFA date. A normal time frame for a PDUFD date to be set is ten months from the date the NDA was submitted. Since the NDA was submitted during the last week of December 2009, the Normal Review PDUFA date would be set for the last week of October 2010. Receiving an accelerated review with either a Fast Track or Priority Review Status would reduce the PDUFA date by a number of months depending on which accelerated status it receives.

In order for a NDA to be classified with an accelerated status the company must request it when they submit the NDA. We have no idea if ANX requested a Fast Track or a Priority Review when they submitted the NDA application.

There are a lot of traders on the many message boards I am a member of, and blogs that I read that think the share price of ANX will skyrocket up once we get the PR that the FDA has accepted the NDA for ANX-530. In all of the years I've been following FDA plays, I've rarely seen a huge move up on just the news that a NDA was accepted.

There may be a nice move up on the day the FDA news is PR'd due to retail buying and maybe a little bit of Short Covering. But as soon as buying volume drys up I have a feeling the Shorts will be adding to their positions again in an attempt to hold this stock down like they've been able to do most of this year.

The only times I've seen a large and sustainable increase in the share price is if the FDA assigns either Fast Track or Priority Status. When that happens, the market really takes notice and the share price soon reflects it.

If the FDA accepts the application that would be very good news for this company because the FDA is not only ruling if the drug ANX-530 is worthy of further review, but more importantly that their proprietary emulsion process also has merit. Every new drug this company has in it's pipeline and plans to submit to the FDA for approval is based on this unique and patentable emulsion technology.

During the past two months, there has been a lot of talk about a buyout, takeover, or partnership of ANX by either GlaxoSmithKline (NYSE-GSK) or Sanofi-Aventis (NYSE-SNY). The reason one or both of these huge drug manufacturing companies would be interested in in taking ANX over is because they both stand to lose a lot of potential market share if ANX's drugs go to market in competition with their existing drugs.

ANX-530 would be in direct competition with GSK's drug Vinorelbine, which has a worldwide annual market estimated at around $200 million. ANX-514 would be in direct competition with SNY's drug Taxotere, which has a worldwide annual market share estimated at around $3 BILLION! Not only would they be removing competition from their existing drugs, but they would also become owners of the proprietary emulsion technology that could be applied to many other existing drugs to make them safer and more effective.

Usually, when a buyout offer is tendered, the offer price is between 300-500% above the current share price. ANX is currently trading at around $0.30 per share so a 300% increase would put the buyout offer at $0.90 and a 500% increase would put the buyout offer at $1.50 The traders that are calling for a buyout offer between $3.00 to $4.00 are dreaming in my opinion.

There are many traders that entered Long positions hoping for buyout to happen, because they have done their research on this company and know it is a definite possibility. If they hold a sizeable position between $0.15 to $0.50 they stand to make a nice profit if a buyout offer is tendered.

I am one of those traders, but I didn't enter my position just because of the possibility of a buyout. I have looked into this company's history, and there has been a lot of good changes made since the previous CEO ran the company. But the bottom line is I think that their technology is fantastic, and it will be able to make many existing drugs much more effective and safer.

Here is a three month/daily chart of ANX. It ran from below $0.10 to $0.52 in the past few months, and it has held half of it's gains which shows a lot of strength and is considered Bullish. Keep this stock on your radar next week, because if the PR comes out saying that the NDA for ANX-530 has been accepted there should be a nice move to the upside. If the FDA assigns an accelerated review process designation, there may be a very large and sustainable move of the share price to the upside. In My Honest Opinion.

Happy Trading,
zigzagman

NASDAQ Stocks to Watch on Monday March 1st, 2010: NUVA - YRCW - RJET

NUVA [NASD] - NuVasive, Inc. - Healthcare - Medical Instruments & Supplies

+$10.31
+34.73%
Volume: 12,541,204
Avg Volume (3month): 1,212,240

NuVasive Reports Fourth Quarter and Full Year 2009 Financial Results:

- Full year 2009 total revenue of $370.3 million; up 48.1% from the full year 2008
- Fourth quarter total revenue of $106.9 million; up 43.4% from fourth quarter 2008 and up 12.7% from third quarter 2009
- GAAP earnings of $2.3 million, or $0.06 per share, for the fourth quarter and $5.8 million, or $0.15 per share, for the full year
- Earnings, excluding certain adjustments, of $4.2 million, or $0.11 per share, for the fourth quarter and $12.3 million, or $0.32 per share, for the full year
- Operating cash flow of $46.4 million for the full year; up from ($5.0) million for the full year 2008

http://finance.yahoo.com/news/NuVasive-Reports-Fourth-prnews-2077312398.html?x=0&.v=1

NUVA had 10X it's average daily volume on Friday, and the biggest volume day in the three months this chart shows after they released end of the year and end of the quarter financial results. It's obvious that the market really liked their report. This stock may continue up on Monday, it may run sideways for a while, or it could pull back drastically. There may be some good scalping opportunities on this stock next week.



YRCW [NASD] - YRC Worldwide Inc. - Services - Trucking

+$.0596
+14.84%
Volume: 106,542,745
Avg Volume (3month): 22,265,200

Trucking companies haul in a freight rebound in January:

http://kansascity.bizjournals.com/kansascity/stories/2010/02/22/daily29.html?ana=yfcpc

YRCW got over five times it's average daily volume on Friday, and had the biggest volume day on this three month chart. All of the technical indicators are upticking sharply, and it appears to me that this one has bottomed. This might be a good time to enter a Swing Trade on this stock, and may also be a good one for Day Trading.



RJET [NASD] - Republic Airways Holdings Inc. - Services - Regional Airlines

+$0.77
+14.47%
Volume: 2,937,103
Avg Volume (3month): 708,386

Republic Airways to buy as many as 80 new jets:

http://finance.yahoo.com/news/Republic-Airways-to-buy-as-apf-1632752983.html?x=0&.v=2

Republic Airways Q4 profit little changed with Frontier Airlines Buy:

http://denver.bizjournals.com/denver/stories/2010/02/22/daily53.html?ana=yfcpc

RJET had over four times it's average daily volume on Friday, and also had it's biggest volume day in the past three months. It has broken above the resistance level at $5.50 and now has little resistance all the way up to the $7.00 area, and all of the technical indicators are upticking. This may be a good time to enter a Swing Trade position on this stock, and there may be some good Day Trading to be done on this one too...



Happy Trading,
Tom

Stocks to Watch for Feb. 26, 2010 - LEHMQ - WAMUQ - LTXC - SMSI - TRLG - CCE:

All of these stocks had unusually high volume, broke out to new highs, or got really interesting news out today:

LEHMQ - Lehman Brothers Holdings Inc.



WAMUQ - Washington Mutual Inc.



LTXC -LTX-Credence Corporation



SMSI - Smith Micro Software Inc.



TRLG - True Religion Apparel Inc.



CCE - Coca-Cola Enterprises Inc.

Stocks to Watch for Feb. 24, 2010 - ANX - ILI - ZLC - CKP - NLS - CDI - CIMT - SOMX

Here are a few stocks to watch on Wednesday February 24th:

AMEX stocks to watch:

ANX - Adventrx Pharmaceuticals, Inc. - Healthcare - Biotechnology



ILI - Interleukin Genetics Inc. - Healthcare - Diagnostic Substances



NYSE stocks to watch:

ZLC - Zale Corporation - Services - Jewelry Stores



CKP - Checkpoint Systems Inc. - Services - Security & Protection Services



NLS - Nautilus Inc. - Consumer Goods - Sporting Goods



CDI - CDI Corp. - Services - Staffing & Outsourcing Services



NASDAQ stocks to watch:

CIMT - Cimatron Ltd. - Technology - Technical & System Software



SOMX - Somaxon Pharmaceuticals, Inc. - Healthcare - Drug Manufacturers



Happy Trading,

zigzagman
Tom

VIDEO: Technical Analysis of ANX - ADVENTRX Pharmaceuticals Daily & Weekly Charts - Feb. 21, 2010:

This is the third weekend I've done the end of the week Fundamental and Technical Analysis of ANX's daily and weekly charts...

We are expecting news in the very near future that will tell us if the FDA has accepted the NDA (new drug application) for their drug candidate ANX-530

Things are about to get VERY interesting with this stock in the next week or two...Stay tuned for recent developments as they happen...

Disclaimer: I hold a lot of shares of ANX, and am VERY Bullish on this company...GLTA

Happy Trading,
zigzagman

Introduction to Time & Sales and Level 2 - Tools for Day Trading:

Day Traders use every tool at their disposal to help them decide when a good time to enter or exit a trade will be.

Time & Sales and Level 2 are two such tools. This video is a brief explanation of how these tools are used to determine if a stock or Exchange Traded Fund (ETF) will go up or down in the next few seconds.

These tools can not be used for Swing Trading or for day trades that last for hours when the market is trending strongly either up or down.

These tools do help when you are doing Scalping types of day trades. Scalping is when you enter a trade that will only last for a few minutes with a large block of shares. When the stock or ETF has moved up or down ten to fifty cents very quickly, that is a good time to exit the position to lock in your profits before the trend reverses.

When I do Scalping trades, I usually buy 1000 to 5000 shares. With 1000 shares, I'm looking for a move in the ten to thirty cent range in five to fifteen minutes. A ten cent move yields $100. and a thirty cent move yields $300.

When I trade 5000 shares, I'm looking for the stock to move five to twenty cents in five to fifteen minutes. A five cent move yields $250. and a twenty cent move yields $1000.

Sometimes I trade using 10,000 shares. Each penny the stock moves in the direction I want it to is worth $100. So if a stock moves ten cents, that yields $1000. usually in less than fifteen minutes.

These tools work better on some stocks or ETF than others. It is hard to use these tools on a stock or an ETF that trades 100 million shares each day. They work best on stocks that trade 5 to 25 million shares per day. The less daily volume a stock gets, the easier it is to see how these tools work.

While I can show you the basics of how these tools work, the only way you will get proficient at reading them is to study them for many hours each day over a period of a few years. If you would like to read more about Time & Sales and Level 2, here is a good article on the subject:

http://www.investopedia.com/Level 2

If you watch the three videos at the top of the Video Charts page of my website that show me doing real-time day trades while the market is open, you'll see that I mention these two tools and show how they work in action.

www.stock-market-lessons.com/videocharts.html



Happy Trading,
zigzagman